Biocon Rises 1.11% After ₹4,500 Cr QIP Launch at ₹340.20; 11.6% Equity Dilution to Follow

Mumbai, 17 June 2025: On June 17, Biocon Ltd (NSE: BIOCON, BSE: 532523) saw its shares climb 1.11% to ₹361.20 in morning trade. The rise came after the company announced a Qualified Institutions Placement (QIP) worth ₹4,500 crore to raise capital under Chapter VI of SEBI ICDR Regulations, 2018.

As of 12:14 PM IST on June 17, Biocon Ltd shares were trading at ₹361.50, marking a gain of ₹4.25 or 1.19% from the previous close. The stock opened at ₹355.00 and moved within a range of ₹353.50 to ₹364.65 during the first half of the trading session. Biocon’s market capitalisation stood at ₹43,310 crore. The stock’s 52-week high and low were ₹404.70 and ₹291.00, respectively. It currently has a P/E ratio of 42.73 and offers a quarterly dividend of ₹0.13, with a yield of 0.14%.

QIP Strengthens Balance Sheet and Drives Stock

Biocon’s ₹4,500 crore QIP, launched at a floor price of ₹340.20, is being used to acquire convertible debentures held by its subsidiary, Biocon Biologics, currently held by Goldman Sachs’ AIF schemes.

Additionally, the capital will aid in repaying or prepaying existing loans, redeeming financial instruments, and fulfilling other financial obligations. This strategic fundraising move improved investor confidence, leading to positive share price movement.

QIP to Dilute 11.6% Equity at Floor Price of ₹340.20

Biocon will issue up to 13.9 crore equity shares, diluting about 11.6% of its current shareholding. The floor price is set at ₹340.20 per share. The plan was approved on June 16, 2025, by the company’s Fund Raising Committee.

QIP Meets SEBI Norms and Insider Trading Restrictions

The QIP is structured under Regulation 176(1) of SEBI’s ICDR Regulations. Disclosures are filed under SEBI LODR Regulations 29(1) and 30. Additionally, Biocon’s trading window remains closed under SEBI’s Insider Trading rules.

CEO Confirms QIP Approval and Pricing Strategy

Managing Director & CEO Siddharth Mittal confirmed that the Fund Raising Committee approved the QIP and floor pricing in its June 16 meeting. He added that the final issue price will be determined in coordination with the Book Running Lead Managers.

FDA Approval of Jobevne™ Bolsters Growth Outlook

In April, Biocon Biologics received U.S. FDA approval for Jobevne™ (bevacizumab-nwgd), its seventh biosimilar in the U.S. This regulatory win in the oncology segment enlarged its global product portfolio and enhanced projected future revenues, providing further tailwinds for the stock.

Company Background and Market Position

Biocon Ltd has been listed on NSE and BSE since April 7, 2004. It is a prominent player in India’s biopharma sector and a constituent of the NIFTY Midcap 100 index. The stock currently trades at an adjusted P/E of 31.56, compared to the sector average of 30.01.

Disclaimer:  At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations